Ozanimod (Zeposia) recommended for European licence
The European Medicines Agency (EMA) has recommended that a licence should be granted for ozanimod (Zeposia) for people with active relapsing remitting MS. Active is defined as people who are having relapses or have new or enlarging lesions on MRI scans.
The next step in the approval process is for the European Commission to grant the licence, taking into consideration the EMA's recommendation. Ozanimod will then be appraised by NICE and SMC to determine availability in the UK.
NICE has started the appraisal process for ozanimod but has put further work on hold to prioritize support for the coronavirus pandemic. The MS Trust is contributing to the appraisal.
About ozanimod
Ozanimod is taken as a tablet, once daily. A low dose is taken initially which is gradually increased over the first week. This reduces the risk of slowing the heart rate.
In a two year clinical trial, ozanimod reduced the risk of relapses by 38% compared to beta interferon (Avonex) and reduced the number of new active lesions seen on MRI.
The most common side effects reported in clinical trials were nasopharyngitis (common cold), reduced white blood cell count, headache, chest infections and urinary tract infections. Ozanimod caused temporary increases in liver enzymes which generally returned to normal levels without the need to stop treatment.
Ozanimod belongs to the same class of drugs as Gilenya (fingolimod). It works by retaining lymphocytes (immune cells) in lymph nodes. The number of lymphocytes reaching the brain is decreased, resulting in a reduced immune attack on nerve cells in the brain and spinal cord.
Find out more


Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.


Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.


Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.

Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.